Unsolved Issues in the Management of High Blood Pressure in Acute Ischemic Stroke

Table 1

Important randomised controlled trials of intervention versus control. SBP: systolic blood pressure, MAP: mean arterial pressure, AH: antihypertensive agents, p.o.: per os, i.v.: intravenous, n.p.: not published. (The phase II trial ACCESS comparing candesartan versus placebo has not been included, as the following phase III trial SCAST has been).

Name	Year of publication	𝑛	Initial median blood pressure (mmHg)	Time to treatment (hours)	Substance	Administration	Stroke subgroup
BEST [21]	1988	302	n.p.	22–25.3	Atenolol, Propanolol	p.o.	Ischemic + hemorrhagic
INWEST [23]	1994	295	SBP 159–161	10.5–11.5	Nimodipine	i.v.	Ischemic
Rashid et al. [27]	2003	90	SPB 151	51	Glyceryl Trinitrate	transdermal	Ischemic + hemorrhagic
IMAGES [25]	2004	2589	MAP 108	7	Magnesium	i.v.	Ischemic + hemorrhagic
CHHIPS [28]	2009	179	SBP 181	17.4–20.5	Labetalol, Lisinopril	p.o., i.v., sublingual	Ischemic + hemorrhagic
COSSACS [29]	2010	763	SBP 150	23.5	Previously taken AH	any	Ischemic + hemorrhagic
SCAST [30]	2011	2029	SBP 171	17.8	Candesartan	p.o.	Ischemic + hemorrhagic